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Strengths and limitations of this study
 ► This project will be the first comprehensive review of 
the molecular characteristics of multiparametric MRI 
(mpMRI)- visible and mpMRI- invisible lesions, fol-
lowing the key methodological steps of the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses guidelines.
 ► Novel bioinformatic over- representation analysis will 
reveal shared pathways and genes involved in pros-
tate cancer mpMRI conspicuity that are overlooked 
by individual studies.
 ► The degree of heterogeneity between the included 
studies limits the comparability of derived results.
 ► There are relatively few studies that directly com-
pare the genomic basis of mpMRI- visible and 
mpMRI- invisible lesions which potentially limits the 
strength of conclusions from this work.
AbStrACt
Introduction The introduction of multiparametric MRI 
(mpMRI) has enabled enhanced risk stratification for men 
at risk of prostate cancer, through accurate prebiopsy 
identification of clinically significant disease. However, 
approximately 10%–20% of significant prostate cancer 
may be missed on mpMRI. It appears that the genomic 
basis of lesion visibility or invisibility on mpMRI may have 
key implications for prognosis and treatment. Here, we 
describe a protocol for the first systematic review and 
novel bioinformatic analysis of the genomic basis of 
prostate cancer conspicuity on mpMRI.
Methods and analysis A systematic search of MEDLINE, 
PubMed, EMBASE and Cochrane databases will be 
conducted. Screening, data extraction, statistical analysis 
and reporting will be performed in accordance with the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) guidelines. Included papers will 
be full text articles, written between January 1980 and 
December 2019, comparing molecular characteristics 
of mpMRI- visible lesions and mpMRI- invisible lesions 
at the DNA, DNA- methylation, RNA or protein level. 
Study bias and quality will be assessed using a modified 
Newcastle- Ottawa score. Additionally, we will conduct a 
novel bioinformatic analysis of supplementary material 
and publicly available data, to combine transcriptomic data 
and reveal common pathways highlighted across studies. 
To ensure methodological rigour, this protocol is written in 
accordance with the PRISMA Protocol 2015 checklist.
Ethics and dissemination Ethical approval will not 
be required, as this is an academic review of published 
literature. Findings will be disseminated through 
publications in peer- reviewed journals, and presentations 
at national and international conferences.
PrOSPErO registration number CRD42019147423.
bACkgrOund
Prebiopsy multiparametric MRI (mpMRI) 
has excellent diagnostic accuracy, and has 
improved risk stratification in prostate cancer 
diagnosis, compared to systematic transrectal 
ultrasound- guided prostate biopsy.1 2 Despite 
this, approximately 10%–20% of clinically 
significant prostate cancers remain mpMRI 
invisible.1 3 4
Suspicious mpMRI phenotypes appear to 
closely associate with the presence of prostate 
cancer, and to an extent, its Gleason grade.1 
However, the degree to which the molecular 
landscape of prostate cancer correlates with 
mpMRI is unclear. In contrast, the general 
molecular basis of prostate cancer is well 
studied, with large- scale genomic enquires 
defining key drivers in tumour development 
and progression. Aberrations, including 
recurrent mutations in SPOP1, FOXA1, 
IDH1, fusions in TMPRSS/ERG, ETV1/4, 
FLI1 and copy number alterations, such 
as MYC amplification or NKX3-1, RB1 and 
PTEN deletions or transcriptomic changes 
in AMACR, PCA3, GDF15 and MSMB, have 
all been investigated in the context of pros-
tate cancer.5–7 Over the past 5 years, there 
has been an increased effort to use this to 
develop our understanding of the genetic 
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Table 1 Data collection items
Item no Data title Data type
1 Year of publication Study characteristic
2 Study authors Study characteristic
3 Study design Study characteristic
4 Patient population Demographics
5 Number of participants Demographics
6 mpMRI scoring scheme 
used
Methodology
7 Definition for clinically 
significant disease
Methodology
8 Definition for lesion 
visibility and invisibility
Methodology
9 Sample processing 
approach
Methodology
10 Biomolecule studied Outcome
11 Differential expression of 
biomolecule
Outcome
mpMRI, multiparametric MRI; no, number.
basis of prostate cancer conspicuity on mpMRI. It is now 
prudent to collate this growing evidence base, to clarify 
on progress made so far, and identify the most pertinent 
areas for future research.
The aim of this systematic review and bioinformatic 
analysis is to determine and summarise for the first time, 
the genomic correlates of tumour visibility and invisibility 
on mpMRI, in order to elucidate the mechanisms that 
underpin mpMRI conspicuity, and the prognostic impli-
cation of mpMRI phenotypes.
MEthOdS And AnAlySIS
This protocol of the planned systematic review and bioin-
formatic analysis is written in line with the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses Protocol (PRISMA- P) 2015 checklist.8 Selected 
studies will be used for thematic synthesis and appro-
priate supplementary material extracted. In addition to 
the literature search, a bioinformatic approach will be 
used to identify relevant publicly available genomic data 
for a comprehensive analysis of over- represented path-
ways and biological functions.
Search methodology
Searches will be carried out using the MEDLINE, 
PubMed, EMBASE and Cochrane databases in order to 
retrieve maximum yield of relevant evidence. The search 
will include Medical Subject Headings terms and free 
text, combined with Boolean operators. The search will 
include the terms: ‘prostate’, ‘cancer’ and ‘MRI’, as well 
as multiple synonyms for the term ‘genetics’, to account 
for large heterogeneity in nomenclature and diversity of 
topics encompassed within this heading. Identified arti-
cles will be uploaded to Rayyan, a semiautomated tool to 
expedite the initial screening process and to allow two 
reviewers to filter duplicate studies and screen articles 
for relevance.9 Furthermore, the reference section of all 
included articles will be searched manually to identify 
missed studies or additional data. Finally, experts will be 
consulted to identify additional literature. Only articles 
published between January 1980 and December 2019 will 
be included in our review. For the bioinformatic analysis, 
the National Center for Biotechnology Information Gene 
Expression Omnibus and European Genome- phenome 
archive will be searched using the same search parame-
ters as those used for the literature search. If sufficient 
processed data are available, data will be extracted from 
supplementary to ensure data veracity. In the case of 
missing data, the corresponding authors will be contacted 
directly.
Study selection and data extraction
Two researchers will independently screen eligible 
studies, assessing titles and abstracts for relevance. If 
considered eligible, the full text will be retrieved and 
further reviewed for eligibility. Any lack of concordance 
between reviewers will be discussed until a consensus is 
reached or passed to a third reviewer. Additionally, the 
reason for exclusion will be noted for later analysis. This 
process will be documented in detail in order to generate 
the PRISMA flow diagram.
Inclusion criteria
To be included in the analysis, studies must investigate one 
or more genomic aspects of the appearance of prostate 
cancer on mpMRI. Genomic investigation could be at the 
DNA level, investigating SNPs or somatic alterations, or 
focused on larger scale alterations, such as copy number 
changes. Moreover, investigations revealing higher order 
structures, such as methylation, will also be included. 
Transcriptomic data analysing RNA expression (coding 
or non- coding) or microRNA will also be included, as will 
investigation into protein expression.
Exclusion criteria
Conference abstracts, correspondence articles, expert 
opinions and case reports will be excluded. Studies 
that do not correlate mpMRI phenotypes with genomic 
data will be excluded. Articles focusing solely on macro- 
characteristics or clinical features of mpMRI conspicuity 
will be removed.
data extraction
All extracted data will be collated in a dedicated data 
sheet. Both reviewers will extract data independently from 
each other and agree on consensus. Table 1 summarises 
data items to be collected.
Endpoints
The primary endpoint will be differential gene expres-
sion between mpMRI- visible and mpMRI- invisible lesions. 
Initial literature searching suggests that the majority of 
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Table 2 Steps in the bioinformatic analysis
Step no Task
Step 1 Identifying studies with suitable supplementary 
data or associated data in data repositories.
Step 2 Assessing comparability of results.
Step 3 Comparing overlapping genes in multiple studies.
Step 4 Over- representation analysis of genes present in 
multiple studies.
Step 5 Comparison of suggested gene panels in 
independent cohort datasets.
no, number.
studies have focused on mRNA expression; therefore, we 
will identify recurring genes which have a significant fold- 
change between visible and invisible lesions. Secondary 
endpoints will include explanatory links between gene 
function and mpMRI conspicuity, and the prognostic 
value of differential gene enrichment. We will identify 
key themes within the literature, with a focus on the MRI 
scoring systems used (eg, Prostate Imaging–Reporting and 
Data System (PI- RADS), Likert, radiogenomic features), 
the criteria used to define lesion visibility (PI- RADS or 
Likert score thresholds) and the type of cohort used in 
the study (eg, radical vs biopsy cohort). Additionally, we 
will identify which studies corrected for histopathological 
features such as lesion size and Gleason grade.
Subgroup analysis
A secondary analysis will look at whether gene panels, 
or individual genes, associated with mpMRI conspicuity 
show different expression levels when key attributes (eg, 
Gleason grade and tumour size) are matched between 
study arms.
Statistical analysis
For the bioinformatic analysis, we will aim to keep data 
as close to the original format that was provided in the 
selected study. In the case of transcriptomic data, we 
will extract Log2 fold change and the associated false 
discovery rate adjusted value between mpMRI- visible and 
mpMRI- invisible tumours. In more complex compar-
isons, we will attempt to extract details which indicate 
concordance of differential gene expression between 
studies; however, we will not include effect size if this 
is incomparable. If unavailable, we will simply compare 
highlighted genomic features and the direction of change 
between groups. Genes highlighted in multiple studies 
will be used (via over- representation analysis) to iden-
tify enriched pathways. This analysis will be performed 
using the WebGestalt: Gene Set Analysis Toolkit.10 This 
method does not rely on effect size weighting and uses a 
modified Fisher’s exact test to identify enriched biolog-
ical processes.11 Steps in the bioinformatic analysis are 
outlined in table 2.
risk of bias in individual studies
To assess bias and quality across the included studies, a 
modified Newcastle- Ottawa score will be used, designed 
to assess observational cohort studies.12 This scoring 
system is split into three main sections: selection, compa-
rability and outcome. Each section contains subques-
tions that assess the quality of the research methodology, 
at the study level. Two reviewers will be involved with 
this process, and any disagreement will be settled by 
consensus. The results of the bias assessment will be used 
to influence data synthesis by providing an assessment of 
the reliability and applicability of the data produced. If 
studies are found to be of low quality (or high bias) then 
they may be excluded, or if included, they will be accom-
panied by appropriate commentary in the discussion. As 
this review centres around genomic studies of conspi-
cuity as opposed to treatment outcome, non- applicable 
sections may be modified to reflect the evidence base and 
reduce reporting inaccuracy.
Patient and public involvement
Patients and the public were not involved in the develop-
ment of this systematic review protocol.
dISCuSSIOn
In the UK, the National Institute for Health and Care 
Excellence have recently updated their guidelines for 
men with suspected prostate cancer.13 Men with suspected 
prostate cancer should now undergo mpMRI before pros-
tate biopsy, as part of their risk stratification.14 This move 
will likely see a rise in the numbers of mpMRI performed, 
and as such, we should strive to better understand the 
nature of disease detected and missed by this technology. 
Through systematic review and bioinformatic analysis, 
we aim to identify commonality between genomic- based 
studies which have investigated mpMRI- visible and 
mpMRI- invisible tumours. Our results will enhance the 
understanding of the genomic basis of prostate cancer 
visibility on mpMRI, the pathways that underpin this 
and, ultimately, the prognostic implication of disease 
conspicuity.
In our thematic analyses, we aim to derive the most 
prominent themes from studies that compare genetic 
differences in mpMRI- visible and mpMRI- invisible 
disease. The mechanistic links between genomic charac-
teristics and the appearance of prostate cancer on mpMRI 
are not clear; however, early evidence suggests that genes 
controlling tumour cell proliferation may impact on 
perfusion, and as such, generation of mpMRI signal, 
particularly on diffusion- weighted imaging sequences.15 
Furthermore, combining suitable studies that link 
tumour conspicuity to genetic control will strengthen our 
understanding. Another important potential theme that 
we aim to elicit is the prognostic implication of different 
mpMRI- visibility or mpMRI- invisibility phenotypes (as 
defined by PI- RADS or Likert scoring schemes).16 It 
appears that mpMRI- visible prostate cancer tends to have 
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higher expression of genes associated with poor prog-
nosis; however, this view is not unanimous throughout the 
literature, and our rigorous systematic analysis will expose 
key differences in expression of prognostically significant 
genes, across different studies.17 18
In our bioinformatic analyses, we will compare large, 
publicly available genomic datasets that are linked to 
included studies from our systematic review. Described 
by Weidman and Arrison as ‘data exploitation’, this 
approach allows effective use of collective information to 
obtain new insights.19 We hope to elucidate commonali-
ties between the strongest molecular differences between 
mpMRI- visible and mpMRI- invisible tumours. Pooling of 
data will strengthen association of particular genes with 
previously described features (eg, molecular pathways and 
prognostic value). Furthermore, bioinformatic compar-
ison of these datasets may reveal potential key targets for 
future research, including the development of periph-
eral biomarkers to identify clinically significant, mpMRI- 
inconspicuous prostate cancer. A potential limitation may 
be data heterogeneity, due to differences in definitions 
for MRI- visibility and methods of identifying genetic 
determinants. Our analysis will attempt to overcome this 
issue by focusing on studies with similar definitions of visi-
bility, and restricting our analyses to identified genes and 
enriched pathways, as opposed to effect sizes.
In summary, this systematic review and novel bioin-
formatic analysis of publicly available genomic data will 
collate extant evidence in this emerging field, for the 
first time. Synthesis of these studies will enhance our 
current understanding of the role that genetics play in 
the mpMRI- conspicuity of prostate cancer, and will clarify 
the most pertinent areas for future research.
trial status
 ► Preliminary searches: started.
 ► Piloting of the study selection process: started.
 ► Formal screening: started.
 ► Data extraction: not started.
 ► Risk of bias assessment: not started.
 ► Data analysis: not started.
draft of search strategy for MEdlInE, EMbASE, PubMed and 
Cochrane databases
(prostate AND cancer) AND (gene OR genetic OR 
genome OR genomic OR transcriptome OR transcrip-
tomic OR epigenetic) AND (magnetic resonance imaging 
OR MRI)
EthICS And dISSEMInAtIOn
Due to the nature of the study, there are no relevant ethical 
concerns and informed consent will not be required. The 
protocol and systematic review will be disseminated via a 
peer- reviewed journal.
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